舒张性心力衰竭大鼠循环及组织交感活性与肾胺酶的相关性研究

目的研究舒张性心力衰竭大鼠模型血浆及心肌组织肾胺酶与交感神经递质多巴胺、肾上腺素、去甲肾上腺素的关系,探讨其在舒张性心力衰竭中的作用。方法采用腹主动脉和左侧肾动脉同时缩窄的方法建立大鼠舒张性心力衰竭模型,通过超声心动图监测和左心导管检查评价舒张性心力衰竭大鼠模型。研究血浆交感神经递质与肾胺酶之间的关系。结果术后12周成功建立舒张性心力衰竭大鼠模型。与假手术组比较,手术模型组大鼠血浆交感神经递质水平明显增高[其中多巴胺(15707.34±2 518.76)ng/ml比(7 731.34±1 162.59)ng/ml,P<0.01;肾上腺素(161.15±36.93)ng/ml比(61.72±13.84)ng/ml,P<0.01;去甲肾上腺素(141.06±50.98)pg/ml比(55.66±20.28)pg/ml,P<0.01],而肾胺酶水平明显降低[(9.33±5.46)pg/ml比(19.07±6.88)pg/ml,P<0.01]。相关分析表明循环肾胺酶与多巴胺、肾上腺素、去甲肾上腺素水平具有负相关关系(相关系数r分别为-0.640、-0.594、-0.528,均为P<0.05),而心肌组织肾胺酶与多巴胺、肾上腺素、去甲肾上腺素水平无明显相关性(相关系数r分别为0.584、0.474、0.194,均为P>0.05)。结论采用联合腹主动脉和左侧肾动脉同时缩窄的方法可以成功建立大鼠舒张性心力衰竭模型,此时肾胺酶在交感神经活性改变中发挥一定作用。     

维持性血液透析患者肾胺酶与肺动脉高压及心率变异性的关系

【摘要】 目的 探讨维持性血液透析患者肾胺酶与肺动脉高压及心率变异性的关系。方法 选取雅安市人民医院及重庆市九龙坡区第二人民医院维持性血液透析患者150例,根据患者肺动脉压力水平,分为肺动脉高压（PA）组（65例）,及非肺动脉高压（非PA）组（85例）,PA组又分为轻度组（32例）、中度组（22例）、重度组（11例）三个亚型。检测患者血清血常规、肝肾功、电解质、血脂、甲状旁腺激素等;心脏彩超检测患者心脏相关指标及肺动脉压力;检测患者血清肾胺酶水平及患者心率变异性相关指标,并行统计学分析。结果 PA各组血清肾胺酶水平较非PA组明显降低(P＜005);相关性分析提示血清肾胺酶水平与肺动脉高压呈负相关（r= 019,P＜005);肾胺酶与心率变异性相关性指标(SDANN、SDNN、PNN50)呈正相关（R值分别为 0458、0438、0529,P＜005）。结论 维持性血液透析患者肾胺酶明显降低,同时肾胺酶与肺动脉压力呈负相关,与心率变异性呈正相关。     

Serum anti mullerian hormone and renalase levels in predicting the risk of preeclampsia

Objective

The aim of the study was to explore the association of serum AMH and Renalase with the risk of preeclampsia thereby assessing them as screening tools, reducing the risk of gravid consequences of preeclampsia.

慢性盐负荷对成年人血清肾胺酶的影响

目的 :观察慢性盐负荷对成年人血清肾胺酶浓度的影响。方法 :选取42例28~65岁的成年人参与为期2周的慢性盐负荷试验,包括3 d基线调查及低盐饮食、高盐饮食各7 d的研究。每个阶段均测量血压,并收集血、尿标本,测定24 h尿钠、钾含量;血清肾胺酶采用酶联免疫吸附(ELISA)法测定。结果:与基线期相比,低盐饮食可显著升高受试者血清肾胺酶水平[(5.10±0.18)比(8.12±0.42)mg/L,P     

血清CXCL10、肾酶的水平变化与狼疮性肾炎病情活动的关系

目的 探讨狼疮性肾炎(LN)患者血清趋化因子配体10(CXCL10)、肾酶的变化及其意义.方法 回顾性选取2016年4月至2018年12月在廊坊市人民医院确诊的LN患者87例(LN组)、慢性肾炎患者90例(对照组).根据系统性红斑狼疮疾病活动度评分(SLEDAI-2000)将LN组分为活动组57例,非活动组30例;根据...     

血清肾胺酶、尿调节素、可溶性尿激酶受体联合检测对糖尿病肾损伤早期诊断的价值分析

目的 探究血清肾胺酶（RNLS）、尿调节素（UMOD）、可溶性尿激酶型纤溶酶原激活物受体（suPAR）联合检测对糖尿病肾损伤早期诊断的价值。方法 选取2020年3月至2021年3月成都市第七人民医院收治的61例糖尿病肾损伤病人为糖尿病肾损伤组,按24 h尿白蛋白排泄率（UAER）分为早期糖尿病肾病组（29例）和临床期糖尿病肾病组（32例）,选取66例糖尿病病人为单纯糖尿病组,另选取同期健康体检者60例为对照组。收集病人的一般临床资料并比较,采用尿素酶法检测血清尿素（UREA）,氧化酶法检测肌酐（Cr）和尿酸（UA）水平,采用酶联免疫吸附法（ELISA）检测血清RNLS、UMOD、suPAR的水平。Pearson相关性分析RNLS、UMOD、suPAR与UREA、Cr、UA以及临床资料的关系。采用受试者操作特征（ROC）曲线分析血清RNLS、UMOD、suPAR联合检测对糖尿病病人发生肾损伤的诊断价值。结果 糖尿病肾损伤组、单纯糖尿病组三酰甘油、总胆固醇、空腹血糖、糖化血红蛋白及血清UREA、Cr、UA、suPAR水平[（133.56±42.68）ng/L,(66.48±17.13)ng...     

肾胺酶与肾交感神经活性在慢性心力衰竭中的作用

目的：探讨肾胺酶与局部肾交感活性在慢性心力衰竭中的作用。方法：测定60例慢性心力衰竭患者和42例对照组血浆肾素（PRA）、血管紧张素Ⅰ（AngⅠ）、血管紧张素Ⅱ（AngⅡ）、肾上腺素（E）、去甲肾上腺素（NE）及肾胺酶活性。观察不同纽约心功能分级（NYHA）心衰患者间PRA及肾胺酶等指标间的差异及相关关系。结果：心衰组PRA、E、NE、AngⅠ活性增高,肾胺酶活性降低。与轻微心衰组相比,严重心衰组肾胺酶活性及左室射血分数降低（P分别为＜0．01、0．034）,N末端脑钠尿肽前体（NT-proBNP）及PRA增高（均P＜0．01）。线性相关分析显示肾胺酶活性与Log NT-proBNP（r＝－0．400,P＝0．002）,Log NE（r＝－0．315,P＝0．014）呈负相关。多因素Logistic回归分析显示,NT-proBNP（OR＝6．962,95％CI＝1．223～39．638）、PRA（OR＝3．736,95％CI＝1．031～13．540）及肾胺酶活性（OR＝0．253,95％CI＝0．069～0．927）是影响NYHA级别高低的独立因素。结论：慢性心衰患者反映肾交感神经活性的指标PRA增加,肾胺酶活性降低,且与心衰严重程度有关。     

The partnership between renalase and ejection fraction as a risk factor for increased cardiac remodeling biomarkers in chronic heart failure patients

Abstract

Objective: Heart failure (HF) represents a huge socio-economic burden. It has been demonstrated, experimentally, that renalase, a newly discovered protein, prevents cardiac hypertrophy and adverse remodeling, which is seen in HF. We postulated the following aims: to investigate associations of renalase with biomarkers of cardiac remodeling: galectin-3, soluble suppression of tumorigenicity, (sST2), growth differentiation factor 15 (GDF-15) and syndecan-1, myocardial stretch (BNP) and cardio-renal axis (cystatin C) in HF patients with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) to determine whether renalase, in combination with left ventricular ejection fraction (LVEF), represents a risk factor for plasma elevation in biomarkers.

Methods: We classified HF patients (n?=?76) according to LVEF (preserved/reduced), applied a median plasma renalase (113?ng/mL) as a cut-off value (low/high) and created four subgroups of HF patients: HFpEF/low renalase (n?=?19), HFrEF/low renalase (n?=?19), HFrEF/high renalase (n?=?32) and HFpEF/high renalase (n?=?6). A control group (n?=?35) consisted of healthy volunteers.

Results: Plasma concentrations of evaluated biomarkers were determined using an ELISA technique and were highest in HF patients with reduced EF (p?<?.001, respectively), and renalase’s positive correlations were obtained relating to all biomarkers: galectin-3 (r?=?0.913; p?<?.001), sST2 (r?=?0.965; p?<?.001), GDF-15 (r?=?0.887; p?<?.001), syndecan-1 (r?=?0.922; p?<?.001), BNP (r?=?0.527; p?<?.001) and cystatin C (r?=?0.844; p?<?.001) and strong and negative correlation with LVEF (r?=??0.456, p?<?.001). Increased renalase, regardless of the EF (preserved/reduced), was shown to be an independent risk factor for an increase in all evaluated cardiac remodeling biomarkers, p?<?.001, respectively. However, increased renalase and reduced EF was the only independent risk factor for BNP and cystatin C elevation, p?<?.001, respectively. Results after multivariable adjustments (age/gender) were identical.

Conclusion: When elevated plasma renalase and HF are present, regardless of EF being reduced or preserved, that represents a significant risk factor for increase in cardiac remodeling biomarker plasma concentrations. However, only elevated renalase and reduced EF demonstrated significance as a risk factor for BNP and cystatin C plasma elevation. Renalase may be considered a promising molecule for the improved predictive abilities of conventional biomarkers and is worthy of further investigation.     

Renalase对肾小管上皮细胞-间充质转分化影响的研究

目的 本研究旨在探讨Renalase是否可以延缓肾脏纤维化。方法 体外培养人近端肾小管上皮细胞,给予TGF-β1和（或）不同浓度的Renalase与细胞共同孵育,观察细胞形态的变化,应用免疫荧光观察E-cadherin、α-SMA的分布和表达情况;应用Western blot（WB）法和RT-PCR检测细胞中E-cadherin、α-SMA的蛋白和mRNA表达,应用WB检测FN和Col-Ⅰ蛋白表达,并检测细胞内信号分子p-Smad-2/3、p-ERK1/2、p-p38水平的变化,探讨其可能的分子生物学机制。结果 给予TGF-β1刺激后,E-cadherin表达下调、α-SMA、FN、Col-Ⅰ表达增加。应用不同浓度Renalase与TGF-β1共孵育细胞,上述现象改善,且呈剂量依赖性。同时,与单独TGF-β1刺激相比,添加Renalase共孵育后,细胞内p-smad 2/3和p-p38表达无明显变化,但p-ERK 1/2表达明显下调,差异有统计学意义。而应用质粒转染过表达ERK信号通路后,Renalase抑制TGF-β1诱导的EMT和纤维化的作用被抵消。结论 本研究首次证实Renalase可以减轻TGF-β1所致的肾小管上皮细胞间充质转分化和纤维化,其机制可能与抑制ERK 1/2信号通路的激活相关,为临床延缓CKD进展提供新的治疗靶点和理论依据。     

Renalase,a catecholamine-metabolising enzyme?

Summary Recently, a new FAD-dependent amine oxidase, renalase, was described. It was secreted by the kidney into the blood and shown to have significant cardiovascular actions, which were attributed to its catecholamine-metabolising activity. The authors concluded that renalase might be an important regulatory factor in human (patho)physiology. The catecholamine-metabolising activity of renalase in plasma contrasts with previous investigations where catecholamines were found to be stable in human plasma, provided autoxidation is prevented by an antioxidant. The claim of catecholamine-metabolising activity of renalase was based on the generation of H₂O₂ during incubation of the enzyme with catecholamines. Careful inspection and calculations of the data lead to the conclusion that the rate of H₂O₂ generation is far too low to be ascribed to enzymatic conversion of catecholamines by renalase. Renalase may well have important cardiovascular functions, but there is no proof that its actions are mediated through catecholamine-metabolising activity.